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The metabolic syndrome –  
What is the value of its identification?
The evolution of the concept of the metabolic 
syndrome
It was in the late 1980s and early 1990s that Gerald Reaven 
proposed that a clustering of abnormalities including increased 
plasma triglyceride (Tgs) levels, decreased high density lipoprotein-
cholesterol (HDL-C) concentration and high blood pressure (BP) 
linked to decreased insulin mediated glucose uptake and impaired 
glucose tolerance (IGT) comprised a syndrome.1 In 1998, the first 
formalised definition of the metabolic syndrome (MS) was proposed 
by a World Health Organization consultation group. The diagnosis of 
MS by the WHO criteria required evidence of insulin resistance (IR) for 
diagnosis.2 It was subsequently pointed out by a position statement 
generated by the American Association of Clinical Endocrinologists 
(AACE) and the American College of Endocrinology (ACE) task 
force, which was set up to provide guidance to clinicians on the 
identification and treatment of the MS, that the identification of IR 
in practice is not accurate due to the lack of standardised methods 
used to quantify plasma insulin concentrations in a laboratory 
setting. They stated that there is no evidence to support an individual 
being defined as insulin resistant, and at increased risk of developing 
any of the abnormalities of the MS, on the basis of plasma insulin 
concentrations alone. The AACE/ACE task force strongly cautioned 
practitioners against trying to identify individuals as IR, by making 
use of laboratory tests to identify fasting plasma insulin levels, in 
order to calculate a fasting insulin:glucose ratio (FIGR) as a surrogate 
marker of IR.3
After the WHO criteria, other criteria came from the National 
Cholesterol Education Program Adult Treatment Panel III (ATP 
III) in 2001. ATP III did not require the identification of IR as part 
of the criteria for diagnosis of the MS. The ATP III criteria made 
the presence of three of the following five features the basis for 
recognition of the MS: abdominal obesity (highly correlated with 
IR), elevated Tgs, reduced HDL-C, elevated BP, and elevated fasting 
glucose (impaired fasting glucose or type 2 diabetes mellitus).4 MS 
is a predictor of CVD and diabetes. When CVD or diabetes develops, 
the MS is often present, and the number of components of the MS 
contributes to increased disease risk and disease progression.2 In 
2005, the International Diabetes Federation (IDF) and the American 
Heart Association/National Heart, Lung, and Blood Institute (AHA/
NHLBI) attempted to address differences in the definitions of the 
MS.5,6 However, differences remained with regard to separate 
recommendations relating to waist circumference cut off points. 
The IDF did not require the WHO criteria of insulin resistance for 
diagnosis, but made abdominal obesity necessary as one of five 
factors (Table I) required in the identification of MS, while highlighting 
waist circumference measurements as a useful screening tool; the 
remainder of the criteria were the same as those set by ATP III.2 
The AHA/NHLBI slightly adjusted the ATP III criteria but did not make 
waist circumference measurements and implied abdominal obesity 
a required criteria for diagnosis. The remaining four criteria were the 
same as defined by the IDF.6 There was, however, no agreement on 
the cut points for waist circumference measurements and abdominal 
obesity between the IDF and AHA/NHLBI. The IDF recommended a 
threshold for waist circumference measurements to be defined for 
people of European origin (Europids) to be 94 cm for men and 80 cm 
for women; the AHA/NHLBI, recommended cut points of 102 and 88 
cm, respectively.2
Is it worthwhile identifying people with MS?
Much time and effort have gone into trying to establish uniform criteria 
for the identification of the MS. Yet controversy still exists around 
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the true value of identifying the MS. A recent scientific statement 
by the IDF, NHBLI, AHA, the World Heart Federation, International 
Atherosclerosis Society and the International Association for the 
Study of Obesity states that the MS is a complex of interrelated risk 
factors for CVD and diabetes, and that the MS is widespread and 
has an increasing incidence worldwide which relates mostly to the 
increased prevalence of obesity and sedentary living.2 Further, a 
syndrome is merely a clustering of factors for which the cause is 
uncertain, and these factors occur simultaneously more often than 
by chance alone.2 The MS does not determine absolute risk [it does 
not contain factors that determine entire risk such as other risk 
assessment tools, for example the Framingham 10 Year risk factor 
analysis for CVD, such as age, gender, smoking, total or low density 
lipoprotein cholesterol levels (LDL-C)]2,10. However, according to 
Alberti et al, patients with the MS have double the risk of developing 
CVD over five to ten years when compared with individuals who do 
not have the syndrome. The risk over a lifetime is most probably 
even greater.2 In addition, the MS confers a fivefold increase in risk 
for type 2 diabetes.2
It appears therefore that the primary merit in identifying individuals 
with the MS is to identify risk for the development of CVD and 
diabetes2 and that perhaps the other value of the syndrome as a 
concept is the obvious utility that the identification of one of the 
CVD risk factors in a patient should prompt search for other risk 
factors.7,10 
It is also worthwhile noting that the criteria used for the identification 
of the MS is far from finite, there are many other signs and 
symptoms that are associated with IR and the MS, including, but not 
limited to, albuminuria, a prothrombotic and pro-inflammatory state 
[plasminogen activator inhibitor-1 and fibrinogen, elevated C-reactive 
protein (CRP), Tumour Necrosis Factor-α (TNFα), Interleukin-6, 
decreased adiponectin levels, hyperuricaemia, elevated White Blood 
Cell (WBC) count, endothelial dysfunction, polycystic ovary syndrome 
(PCOS), non-alcoholic fatty liver disease (NAFLD) and others].2,3,7,9 
Furthermore even though an individual may or may not be identified 
as having the MS, it is strongly recommended that signs and 
symptoms associated with the MS should be treated individually 
and aggressively as each one will confer a degree of risk to the 
development of chronic disease and specifically CVD.8
Apart from identification of an increased risk specifically for the 
development of CVD or diabetes, and using the identification of the 
MS as a indication for early medical intervention and prevention 
strategies, perhaps the most valuable lessons that are taught to us by 
the MS is confirmation that certainly obesity, poor dietary practices 
and reduced activity levels interacting with genetic and metabolic 
factors almost guarantee a complex metabolic derangement that in 
turn is associated with disease.10,11 
Can we connect the dots?
One of the primary reasons for identifying a disease process, as in this 
case the MS, would be to understand its cause and provide guidelines 
for prevention, if possible, appropriate treatment intervention and 
resolution of the disease state.7,8,10 Unfortunately, the exact cause of 
the MS still appears to be elusive and as a result some controversy 
still exists about whether the MS is a true syndrome or a mixture 
of unrelated phenotypes.2 A number of suggestions regarding the 
clustering of abnormalities and their precipitating cause(s) have been 
discussed and explored in the medical literature, and certainly there 
is no definitive answer at this time. Insulin resistance has, however, 
been identified as an underlying factor7 and variability in insulin 
sensitivity has been largely attributed to differences in adiposity 
(25%), fitness (25%) and genetics (50%).8 However, a hypothesis 
that seems to hold some further value, is the concept of oxidative 
stress as a pathogenic mechanism underlying insulin resistance, 
diabetes and cardiovascular disease.12 
Poor diet quality and a hypercaloric diet-link with 
oxidative stress and insulin resistance
Muscle and adipose tissue are primarily involved with the 
development of insulin resistance. When energy intake exceeds 
energy expenditure, there is a substrate-induced increase in the citric 
acid cycle, which in turn generates an excess of mitochondrial NADH 
(mNADH) and consequent reactive oxygen species (ROS). It has been 
proposed that muscle and adipose tissue cells protect themselves 
against harmful effects of ROS, by reducing the formation of ROS 
and/or enhancing the removal of ROS. Preventing a build-up of 
mNADH is achieved by inhibiting insulin-mediated glucose disposal 
and inhibiting the entrance of substrates (pyruvate, fatty acids) into 
the mitochondria, this in turn helps to attenuate the formation of 
ROS. It has been proposed that excessive NADH generation can be 
prevented through the inhibition of free fatty acid (FFA) oxidation. 
An increase in intracellular FFA in the cell cytoplasm, in turn, leads 
to reduced levels of insulin sensitive glucose transporter GLUT4 
(C-GLUT4) translocation to the cell membrane, resulting in resistance 
to insulin mediated glucose disposal in muscle and adipose tissue. 
According to this hypothesis, IR can be considered a compensatory 
mechanism that develops to protect cells against further glucose 
and fatty acid uptake and therefore oxidative damage.12
Many studies support this hypothesis in that antioxidants have been 
shown to improve insulin sensitivity. Several clinical trials have 
demonstrated that treatment with vitamin E, vitamin C, or glutathione 
improves insulin sensitivity in insulin-resistant individuals. The 
recent finding that insulin resistance is associated with reduced 
intracellular antioxidant defence status in humans also support this 
hypothesis.12
The link with β-cell dysfunction and endothelial 
dysfunction – key features of the MS
It is rational to suggest that what occurs in muscle and fat cells may 
also take place in other cells, specifically in α-cells and endothelial 
Table I: Criteria for clinical diagnosis of the metabolic syndrome2
Measure Categorical Cut Points
The presence of 3 of 5 risk factors constitutes a diagnosis of the metabolic syndrome
Elevated waist circumference* Population- and  
country-specific definitions
Elevated triglycerides (drug treatment for 
elevated triglycerides is an alternate indicator†) 
≤ 1.7 mmol/L
Reduced HDL-C (drug treatment for ≤ 1.0 mmol/L in males
reduced HDL-C is an alternate indicator†) ≤ 1.3 mmol/L in females
Elevated blood pressure (antihypertensive 
drug treatment in apatient with a history of 
hypertension is an alternate indicator)
Systolic ≥ 130 and/or 
diastolic ≥ 85 mm Hg
Elevated fasting glucose‡ (drug treatment of 
elevated glucose is an alternate indicator) 
≤ 5,6 mmol/L
HDL-C indicates high-density lipoprotein cholesterol.
* It is recommended that the IDF cut points be used for non-Europeans and either the IDF or AHA/NHLBI 
cut points used for people of European origin until more data are available.
† The most commonly used drugs for elevated triglycerides and reduced HDL-C are fibrates and 
nicotinic acid. A patient taking one of these drugs can be presumed to have high triglycerides and low 
HDL-C. High-dose Ω-3 fatty acids presumes high triglycerides.
‡ Most patients with type 2 diabetes mellitus will have the metabolic syndrome by the proposed criteria.
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cells. What is more, these types of cells may be even more severely 
affected by a hypercaloric diet. α-cells and endothelial cells are 
not dependent on insulin for glucose disposal, which is achieved 
via facilitative diffusion.12 When such cells are exposed to elevated 
levels of glucose or fatty acids, they are not able to down regulate 
the influx of nutrients through insulin resistance, and have to permit 
intracellular concentrations of these nutrients to increase. Ongoing 
exposure to high glucose and/or elevated FFA levels, or a combination 
of both, has been suggested by a number of research papers to be 
responsible for α-cell dysfunction and apoptosis.12 It is also important 
to note that these cells are highly vulnerable to ROS, as antioxidant 
enzymes are in short supply in these cells. It has been shown that 
oxidative stress has the ability to damage mitochondria and in turn 
result in a markedly blunted insulin secretion by α-cells.12
It is well known that IR is associated with endothelial dysfunction, and 
there is evidence that indicates that oxidative stress is associated 
with endothelial dysfunction, which in turn contributes to CVD. 
Glucose and FFA overload can be expected to influence endothelial 
cells as they do α-cells via oxidative stress, and a number of studies 
confirmed such a relationship.12 There is also convincing evidence 
that FFA may produce the same consequences and increase 
oxidative stress and induce endothelial dysfunction, which can be 
reversed by antioxidants.12
Oxidative stress, Inflammation and Insulin resistance
The idea that oxidative stress is the common denominator 
underlying insulin resistance, CVD and type 2 diabetes, may 
explain the occurrence of inflammation in all these conditions. It is 
also well known that inflammation is one of the consequences of 
oxidative stress, and the mechanism that generates the mediators 
of inflammation include adhesion molecules and interleukins.12 It is 
also worthwhile recognising that the subclinical pro-inflammatory 
state observed in many conditions including atherosclerosis, ageing 
and cancer, may well be associated with an over-production of free 
radicals by the mitichondria. This theory is supported by in vivo 
studies, showing that glucose and FFA cause inflammation through 
oxidative stress, and they have a cumulative and independent effect, 
and that antioxidants can, at least partially, ameliorate/reverse the 
occurrence.12
The way forward
The abnormalities associated with the MS can be viewed in 
clusters or independently. What is known currently is that these 
abnormalities are indicative of a metabolic derangement associated 
with increased disease risk specifically for cardiovascular disease 
and diabetes. We do not know categorically at present what the 
exact causes of the syndrome’s many abnormalities are, or, for 
that matter, why most abnormalities do not occur collectively in all 
individuals. What is clear though is that obesity, inactivity and diet 
quality play a pivotal role in preventing and treating the MS and/or 
its associated abnormalities and, by inference at this stage, chronic 
disease. Genetic predisposition is clearly an uncontrollable risk 
factor, but those predisposed to diabetes and CVD would be in need 
of more intensive intervention(s) and would need stricter adherence 
to the recommended dietary and lifestyle practices to prevent or 
treat abnormalities associated with the MS and end-stage disease. 
It appears therefore that practitioners should continue to advise 
patients on what they always have done regarding diet and lifestyle 
change, with some necessary adjustments toward improved diet 
quality and improved micronutrient intake, which current evidence 
suggests may well play a key role in preventing oxidative stress, 
inflammation and IR. 
Weight loss has been known to improve features of the MS and 
it has also been shown to reduce oxidative stress and to improve 
each component of the MS.3,10 Practitioners should promote a 
low glycaemic load (GL) diet, as high GL diets have been linked 
with cardiovascular events and glucose spikes with endothelial 
dysfunction.10,14,16 
Inflammation is an integral part of the MS that is worsened by the 
pro-inflammatory profile of the western diet. The available evidence 
is mostly supportive of benefits to be derived from diets rich in 
omega-3 fatty acids and other unsaturated fats, natural antioxidants 
in fruit and vegetables, and fibre in nuts and whole grains by patients 
with the MS.10,15
Supplementation with omega-3 fatty acids is an emerging treatment 
modality and should be strongly considered in patients unable to 
consume the required two fatty fish meals per week10,13. Additionally, 
one should encourage regular exercise – “a little is good and more is 
better” 10 ,and finally, referral to a dietitian should be considered for 
long-term reinforcement and follow up.10
Conclusion
The value of identifying the MS would appear to be a prudent 
approach  for “quantifying” individual risk for CVD and diabetes 
and the presence of symptoms and signs of the syndrome  should 
be accompanied by a search for other comorbidities. Risk factors 
for CVD, whether identified in clusters or separately should be 
treated appropriately, regardless of a diagnosis of the MS. Diet and 
lifestyle changes remain the cornerstone of treatment for the MS 
and associated abnormalities whether they present in clusters or 
individually. Greater emphasis needs to be placed on diet quality 
and intake of micro-nutrients, and, more specifically, nutrients with 
antioxidant properties.
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